Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryusuke Hatae

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Cancer Medicine|April 10, 2021
Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastomaYusuke Funakoshi, Nobuhiro Hata, Kosuke Takigawa, et al.
Scientific Reports|October 1, 2020
Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumorsYuhei Sangatsuda, Fumihito Miura, Hiromitsu Araki, et al.
JCI Insight|December 20, 2019
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapyRyusuke Hatae, Kenji Chamoto, Young Hak Kim, et al.
Journal of Neuro-Oncology|February 6, 2020
First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomideNobuhiro Hata, Masahiro Mizoguchi, Daisuke Kuga, et al.
Clinical Neuroradiology|January 20, 2026
Time-intensity Profiles and T1-corrected Arterial Transit Time from Multi-delay Pseudo-continuous ASL with a Variable-TR Scheme for the Characterization of Adult-type Diffuse GliomaKoji Yamashita, Makoto Obara, Kazufumi Kikuchi, et al.
Journal of Neuropathology and Experimental Neurology|February 14, 2026
Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratificationNayuta Higa, Toshiaki Akahane, Seiya Yokoyama, et al.
Neuro-Oncology Advances|May 16, 2025
Comparative evaluation of CAR-expressing T-, NK-, NKT-cells, and macrophages in an immunocompetent mouse glioma modelRyusuke Hatae, Payal B Watchmaker, Akane Yamamichi, et al.
Neuro-Oncology|August 4, 2021
Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic micePavlina Chuntova, Yafei Hou, Ryosuke Naka, et al.
Cancer & Metabolism|November 20, 2024
Glutaminolysis is associated with mitochondrial pathway activation and can be therapeutically targeted in glioblastomaKenji Miki, Mikako Yagi, Ryusuke Hatae, et al.
Frontiers in Immunology|July 16, 2021
CD206 Expression in Induced Microglia-Like Cells From Peripheral Blood as a Surrogate Biomarker for the Specific Immune Microenvironment of Neurosurgical Diseases Including GliomaShunya Tanaka, Masahiro Ohgidani, Nobuhiro Hata, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Cancer Medicine|April 10, 2021
Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastomaYusuke Funakoshi, Nobuhiro Hata, Kosuke Takigawa, et al.
Scientific Reports|October 1, 2020
Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumorsYuhei Sangatsuda, Fumihito Miura, Hiromitsu Araki, et al.
JCI Insight|December 20, 2019
Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapyRyusuke Hatae, Kenji Chamoto, Young Hak Kim, et al.
Journal of Neuro-Oncology|February 6, 2020
First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomideNobuhiro Hata, Masahiro Mizoguchi, Daisuke Kuga, et al.
Clinical Neuroradiology|January 20, 2026
Time-intensity Profiles and T1-corrected Arterial Transit Time from Multi-delay Pseudo-continuous ASL with a Variable-TR Scheme for the Characterization of Adult-type Diffuse GliomaKoji Yamashita, Makoto Obara, Kazufumi Kikuchi, et al.
Journal of Neuropathology and Experimental Neurology|February 14, 2026
Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratificationNayuta Higa, Toshiaki Akahane, Seiya Yokoyama, et al.
Neuro-Oncology Advances|May 16, 2025
Comparative evaluation of CAR-expressing T-, NK-, NKT-cells, and macrophages in an immunocompetent mouse glioma modelRyusuke Hatae, Payal B Watchmaker, Akane Yamamichi, et al.
Neuro-Oncology|August 4, 2021
Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic micePavlina Chuntova, Yafei Hou, Ryosuke Naka, et al.
Cancer & Metabolism|November 20, 2024
Glutaminolysis is associated with mitochondrial pathway activation and can be therapeutically targeted in glioblastomaKenji Miki, Mikako Yagi, Ryusuke Hatae, et al.
Frontiers in Immunology|July 16, 2021
CD206 Expression in Induced Microglia-Like Cells From Peripheral Blood as a Surrogate Biomarker for the Specific Immune Microenvironment of Neurosurgical Diseases Including GliomaShunya Tanaka, Masahiro Ohgidani, Nobuhiro Hata, et al.
Pageof 7